In the case of MEF2D-rearranged B-ALL, targeting its downstream regulatory factors, such as histone deacetylase 9 (HDAC9), may represent a more effective therapeutic strategy [98]. The gene discussed is MEF2D; the disease is precursor B-cell acute lymphoblastic leukemia.